Literature DB >> 26696623

Reinstitutionalizing transparency at Health Canada.

Matthew Herder1.   

Abstract

Year:  2015        PMID： 26696623      PMCID： PMC4754190          DOI： 10.1503/cmaj.150765

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Transparency in drug regulation: mirage or oasis?

Authors:  Joel Lexchin; Barbara Mintzes
Journal:  CMAJ       Date:  2004-11-23       Impact factor: 8.262

2.  Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship.

Authors:  Joel Lexchin
Journal:  Healthc Policy       Date:  2013-11

3.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.

Authors:  David J Graham; David Campen; Rita Hui; Michele Spence; Craig Cheetham; Gerald Levy; Stanford Shoor; Wayne A Ray
Journal:  Lancet       Date:  2005 Feb 5-11       Impact factor: 79.321

4.  Why we need easy access to all data from all clinical trials and how to accomplish it.

Authors:  Peter C Gøtzsche
Journal:  Trials       Date:  2011-11-23       Impact factor: 2.279
  4 in total
  1 in total

1.  Increasing the transparency of clinical data.

Authors:  Pierre Sabourin; Supriya Sharma
Journal:  CMAJ       Date:  2017-03-27       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.